Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 6.5 -2.84% -0.19
CATB closed up 7.21 percent on Thursday, January 17, 2019, on 4.33 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Up
See historical CATB trend table...

Date Alert Name Type % Chg
Jan 17 Pocket Pivot Bullish Swing Setup -2.84%
Jan 17 Volume Surge Other -2.84%
Jan 17 Calm After Storm Range Contraction -2.84%
Jan 17 Wide Bands Range Expansion -2.84%
Jan 17 Above Upper BB Strength -2.84%
Jan 17 Overbought Stochastic Strength -2.84%
Jan 17 Up 3 Days in a Row Strength -2.84%
Jan 17 Up 4 Days in a Row Strength -2.84%
Jan 17 Upper Bollinger Band Touch Strength -2.84%
Jan 16 Crossed Above 50 DMA Bullish 4.17%

Older signals for CATB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
Is CATB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.8
52 Week Low 3.6
Average Volume 83,434
200-Day Moving Average 9.4064
50-Day Moving Average 5.7064
20-Day Moving Average 4.9635
10-Day Moving Average 5.489
Average True Range 0.5855
ADX 57.85
+DI 42.8691
-DI 3.7048
Chandelier Exit (Long, 3 ATRs ) 5.1435
Chandelier Exit (Short, 3 ATRs ) 5.3565
Upper Bollinger Band 6.3655
Lower Bollinger Band 3.5615
Percent B (%b) 1.12
BandWidth 56.492394
MACD Line 0.1111
MACD Signal Line -0.1434
MACD Histogram 0.2544
Fundamentals Value
Market Cap 150.4 Million
Num Shares 22.5 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -3.91
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.56
Resistance 3 (R3) 7.53 7.22 7.42
Resistance 2 (R2) 7.22 7.00 7.23 7.37
Resistance 1 (R1) 6.95 6.86 7.09 6.98 7.32
Pivot Point 6.64 6.64 6.70 6.65 6.64
Support 1 (S1) 6.37 6.42 6.51 6.40 6.06
Support 2 (S2) 6.06 6.28 6.07 6.01
Support 3 (S3) 5.79 6.06 5.97
Support 4 (S4) 5.82